Prodia Diagnostic Line Targets Double-Digit Growth Through 2026 Business Expansion
PT Prodia Diagnostic Line Tbk (PRDL) is targeting double-digit growth in revenue and net profit for 2026. Following a significant performance surge throughout 2025, the medical diagnostic equipment issuer, which officially listed on the Indonesia Stock Exchange (IDX) on 9 July 2026, is preparing an expansion strategy involving new product launches, wider distribution networks, and increased market penetration.
Cristina Sandjaja, President Director of PT Prodia Diagnostic Line Tbk, stated that the company is optimistic about maintaining the growth rate achieved last year. “Our hope is that this year we can maintain the same growth level as last year, which was above 20%,” Cristina told Kontan on Thursday (9/7/2026).
To achieve this target, PRDL has prepared several strategies. The company will strengthen customer loyalty by improving service quality, expanding its distribution network, and introducing several new diagnostic products that are not yet available in the Indonesian market. Currently, PRDL operates through approximately 70 distributors covering 38 provinces and around 300 regencies/cities. However, the company sees significant room for expansion, as approximately 200 regencies/cities in Indonesia are not yet covered by its distribution network.
Regarding innovation, PRDL has scheduled the launch of several new products starting from the second half of 2026. These products are expected to expand the company’s portfolio and strengthen its competitiveness in the medical diagnostic equipment market. PRDL also views the prospects of the in vitro diagnostics (IVD) industry in Indonesia as highly promising.
One opportunity targeted by the company stems from the government’s Free Health Check-up Programme. From the Ministry of Health’s total budget of Rp 2.6 trillion in 2026, PRDL estimates a potential market of approximately Rp 2.2 trillion for nine types of examinations that align with its product portfolio. The company also relies on its track record in government procurement projects. Previously, PRDL won a tender for lipid profile reagent procurement worth Rp 90 billion in 2023, as well as procurement for cardiovascular disease screening tools and APRI Scores for liver cancer detection in 2025. To date, PRDL has served over 7,600 end-users, including community health centres (puskesmas), hospitals, and both public and private clinical laboratories across Indonesia.
To support this expansion, PRDL is utilising funds from its initial public offering (IPO) held on 9 July 2026. From this corporate action, the company raised fresh capital of Rp 62.75 billion. Of this amount, Rp 35.66 billion will be used to repay part of credit facilities at PT Bank Central Asia Tbk (BBCA) and PT Bank Pan Indonesia Tbk (PNBN). Approximately 28.18% of the IPO funds are allocated for capital expenditure, including the purchase of machinery, calibration equipment, operational vehicles, software, production area re-layout, and the expansion of AHU Biomolecular Laboratory facilities. The remaining funds will be used for raw material purchases, research and development, and marketing activities.
Market response to PRDL shares has been positive. At the close of trading on Friday (31/7), PRDL shares stood at Rp 272, up 7.94% from the previous day. Since its listing on the IDX, the company’s share price has strengthened by approximately 67.9%.